How are we looking after prostate cancer?

QJM: An International Journal of Medicine

Volumn 96, Issue 1, 2003, Pages 75-79

  Waxman, J ^a   Mazhar, D ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST;

ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RESEARCH; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL OBSERVATION; DIET; FAMILY HISTORY; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR;

EID: 0037257191     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hcg009     Document Type: Article

References (29)

1. ONS. Cancer Registrations in England, 1998. 27 September 2001.
2. ONS. Cancer Trends in England and Wales, 1950-1999, Appendix 1. 24 May 2001.
3. ONS. Mortality Statistics: Cause, 2000. Series DH2 no. 27, 2002.
4. ONS. Mortality Statistics: General, 1998. Series DH1 no. 31, 2000.
5. Narod SA, Dupont A, Cusan L, Diamond P, Gomez JL, Suburu R, Labrie F. The impact of family history on early detection of prostate cancer. Nature Med 1995; 1:99-101.
6. Visakorpi T, Kallioniemi AH, Syvänen A-C, et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995; 55:342-7.
7. Schuurman AG, van den Brandt PA, Dorant E, Goldbohm RA. Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study. Br J Cancer 1999; 80:1107-13.
8. Polascik TJ, Pound CR, de Weese TL, Walsh PC. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. Urology 1998; 51:884-9.
9. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlen BJ. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347:781-9.
10. Gerber GS, Thisted RA, Scardino PT, Frohmuller HG, Schroeder FH, Paulson DF, Middleton AW Jr, Rukstalis DB, Smith JA Jr, Schellhammer PF, Ohori M, Chodak GW. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996; 276:615-19.
11. Imperato PJ, Nenner RP, Will TO. Trends in radical prostatectomy in New York Sate. Am J Med Qual; 11:205-13.
12. Feneley MR, Gillatt DA, Hehir M, Kirby RS. A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome. Br J Urol 1996; 78:911-18.
13. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick DG. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer 1997; 79:337-44.
14. Crook J, Esche B, Futter N. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder and sexual function: the patient's perspective. Urology 1996 March; 47:387-94.
15. Vicini FA, Kini VR, Spencer W, Diokno A, Martinez AA. The role of androgen deprivation in the definitive management of clinically localized prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 1999; 43:707-13.
16. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997; 15:1013-21.
17. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360:103-6.
18. Langley SE, Laing R. Prostate brachytherapy has come of age: a review of the technique and results. BJU Int 2002; 89:241-9.
19. Talcott JA, Clark JA, Stark PC, Mitchell SP. Long-term treatment related complications of beachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 2001; 166:494-9.
20. Davis JW, Kuban DA, Lynch DF, Schellhammer PF. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 2001; 166:947-52.
21. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001; 166:876-81.
22. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J. Results of conservative management of clinically localized prostate cancer. N Eng J Med 1994; 330:242-8.
23. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349:906-10.
24. Edelfsen KL, Mandelson MT, McIntosh MW, Andersen MR, Wagner EH, Urban N. Prostate-specific antigen for prostate cancer screening: do physician characteristics affect its use? Am J Prev Med 1999; 17:87-90.
25. Savage P, Bates C, Abel P, Waxman J. British urological surgery practice: 1. Prostate cancer. Br J Urol 1997; 79:749-54.
26. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355:1491-8.
27. Wang YC, Lee HS, Chen SK, Chang YY, Chen CY. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer 1999; 35:226-30.
28. ONS. Mortality Statistics: Cause, 2000. Series DH2 no. 27,2002.
29. Waxman J, Gibson II. Britain needs a national cancer institute. Br Med J 1998; 317:1397A.